Pulmonary arterial hypertension: screening challenges in systemic sclerosis and future directions. Issue 5 (11th May 2017)

• Record Type: Journal Article
• Authors: Diab, Nermin; Hassoun, Paul M.
• Is Part Of: European respiratory journal. Volume 49:Issue 5(2017)
• Publication Date: 2017-05-11
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00522-2017
• Languages: English
• ISSNs: 0903-1936

Abstract

Despite the advent of multiple medical therapies for pulmonary arterial hypertension (PAH), there is currently no cure available for this disease which continues to impose a very heavy burden of morbidity and mortality on afflicted patients. Survival on medical therapy is at best 7 years in patients with idiopathic PAH [1] and significantly less in patients with associated PAH (APAH), such as those with connective tissue disease (CTD) and particularly with scleroderma-associated PAH (SSc-PAH), where median survival is about 4 years. Screening for PAH is significant in scleroderma as it may lead to early diagnosis and initiation of therapy http://ow.ly/TR6230aqRgq